Larotrectinib has been given a positive opinion by NICE, following the submission of a revised price after it was previously rejected.
List view / Grid view
Filter the results
European Pharmaceutical Review investigates five of the latest cancer drug approvals and clinical trial results.
A new report has revealed Johnson & Johnson as the most valuable pharmaceutical brand, despite a decrease in profits from last year.
Preliminary agenda and speakers announced for LogiPharma, The World’s Leading Pharma Supply Chain Event (21 – 23 April) 2020.
FDA approves Nubeqa (darolutamide) as a new treatment for men with non-metastatic castration-resistant prostate cancer.
Two lots of Kogenate® FS vials actually contain the FVIII hemophilia A treatment, Jivi®.
A New Drug Application has been made to the US Food and Drug Administration for the drug darolutamide to treat non-metastatic prostate cancer...
The FDA has accepted the NDA and granted Priority Review for larotrectinib for advanced or metastatic solid tumours harbouring a NTRK gene fusion...
Validation University offers a customisable, hands-on training for immediate, actionable results.